SCHEMBL3344444

SCHEMBL3344444

[CH2]CCNC(=O)c1cnc(C)cn1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.59
RAB9A P51151 5/20 0.59
ALDH1A1 P00352 4/20 0.52
L3MBTL1 Q9Y468 3/20 0.52
POLB P06746 3/20 0.52
HPGD P15428 2/20 0.52
CYP3A4 P08684 2/20 0.52
CYP2C9 P11712 2/20 0.52
CYP2C19 P33261 2/20 0.52
CYP1A2 P05177 1/20 0.52
ATM Q13315 1/20 0.52
TDP1 Q9NUW8 2/20 0.48
SMN1; SMN2 Q16637 5/20 0.48
GAA P10253 1/20 0.48
TSHR P16473 2/20 0.47
NPSR1 Q6W5P4 1/20 0.47
KDM4E B2RXH2 2/20 0.47
BLM P54132 2/20 0.47
TNKS O95271 1/20 0.46
MAPT P10636 3/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6429451 0.86 NPC1 (0.55) NPC1RAB9AALDH1A1L3MBTL1POLB
SCHEMBL26048300 0.83 NPC1 (0.59) NPC1RAB9AALDH1A1L3MBTL1POLB
Hydrochloric Acid SCHEMBL3450092 0.80 NPC1 (0.56) NPC1RAB9AALDH1A1L3MBTL1POLB
SCHEMBL2629368 0.78 NPC1 (0.54) NPC1RAB9AALDH1A1L3MBTL1POLB
SCHEMBL10205813 0.78 L3MBTL1 (0.56) NPC1RAB9AALDH1A1L3MBTL1POLB
SCHEMBL10603927 0.78 NPC1 (0.54) NPC1RAB9AALDH1A1L3MBTL1POLB
SCHEMBL13762268 0.77 NPC1 (0.53) NPC1RAB9AALDH1A1L3MBTL1POLB
SCHEMBL19508074 0.77 NPC1 (0.76) NPC1RAB9AALDH1A1L3MBTL1POLB
SCHEMBL19236117 0.77 NPC1 (0.80) NPC1RAB9AALDH1A1L3MBTL1POLB
SCHEMBL1874036 0.77 NPC1 (0.54) NPC1RAB9AALDH1A1L3MBTL1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
WO-2010038081-A2 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2010-04-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF SDHA, SDHB, UROD NPC1 603/4885RAB9A 2449/4885ALDH1A1 530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.